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Abstract
It has been hypothesized that dedicated optimized Absorb BVS implantation techniques might mitigate the risk of adverse 
events such as target vessel failure and device thrombosis. In this explorative AIDA trial QCA substudy, we sought to inves-
tigate the influence of implantation techniques on lesion-oriented outcomes in both the Absorb BVS and Xience EES arm 
at complete 3-year follow-up. The current analysis includes 2152 study lesions treated with at least one study device, of 
which the baseline angiogram was suited for offline QCA analysis, including Dmax analysis. The lesion-oriented composite 
outcome (LOCE) of this analysis was a composite of definite device thrombosis, target lesion revascularization and target-
vessel myocardial infarction. In Absorb BVS, the Lesion-oriented composite endpoint (LOCE) occurred numerically less in 
correctly QCA sized vessels when compared to incorrectly sized vessels 8.5% (58/696) versus 11.1% (39/358), p = 0.151. 
In Xience EES, LOCE had occurred more frequently in incorrectly sized devices according to device diameter/RVD match-
ing; 2.2% (4/187) in correctly sized devices versus 7.1% (63/911) in incorrectly sized devices (p = 0.014). In this AIDA trial 
QCA substudy, rates of LOCE were significantly lower in Xience EES treated lesions in which devices were correctly sized 
according to the definitions of device diameter/RVD matching.
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Abbreviations
Absorb BVS  Absorb bioresorbable vascular scaffold
Dmax  Maximum diameter
LOCE  Lesion oriented composite endpoint
MACE  Major adverse cardiac events
MLD  Minimum lumen diameter
PCI  Percutaneous coronary intervention
TLF  Target lesion failure
TLR  Target lesion revascularization
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1055 4-019-01756 -w) contains 
supplementary material, which is available to authorized users.
 * Joanna J. Wykrzykowska 
 j.j.wykrzykowska@amc.uva.nl; 
joannawykrzykowska70@gmail.com
1 Department of Clinical and Experimental Cardiology, Heart 
Center, Amsterdam Cardiovascular Sciences, Amsterdam 
UMC, University of Amsterdam, Meibergdreef 9, 
1105 AZ Amsterdam, The Netherlands
2 The Department of Cardiology, Onze Lieve Vrouwe 
Gasthuis, Amsterdam, The Netherlands
3 The Department of Cardiology, Medical Center Leeuwarden, 
Leeuwarden, The Netherlands
4 The Department of Cardiology, Tergooi Hospital, Blaricum, 
The Netherlands
5 The Department of Cardiology, Albert Schweitzer Hospital, 
Dordrecht, The Netherlands
6 ThoraxCenter, Erasmus Medical Center, Rotterdam, 
The Netherlands
7 NHLI, Imperial College London, London, UK
 The International Journal of Cardiovascular Imaging
1 3
TVF  Target vessel failure
TV-MI  Target vessel myocardial infarction
QCA  Quantitative coronary angiography
Xience EES  Xience everolimus eluting stent
Introduction
Coronary bioresorbable scaffolds have been designed to 
overcome the limitations of metallic drug eluting stents 
which are caused by permanent caging of the coronary 
artery [1]. The most widely studied and implanted coro-
nary scaffold is the Absorb bioresorbable vascular scaffold 
(Absorb BVS) (Abbott Vascular, Santa Clara, USA). Ini-
tial short and mid-term results of the first trials, in which 
Absorb BVS was used, were promising. Larger randomized 
trials reported alarming rates of device thrombosis when 
compared to Xience everolimus eluting stent (EES) (Abbott 
Vascular, Santa Clara, USA) [2–4]. The Absorb BVS has 
thicker struts, a lower radial strength and a limited ability to 
over-expand, when compared to conventional metallic drug-
eluting stents (DES) [5]. These limitations make the Absorb 
BVS less forgiving and harder to optimally implant. Subopti-
mal implanted stents and scaffolds have been associated with 
higher rates of adverse events [6, 7]. It has therefore been 
hypothesized that dedicated optimized Absorb BVS implan-
tation techniques might mitigate the risk of adverse events 
such as target vessel failure and device thrombosis [8, 9]. 
The exact definitions of dedicated Absorb BVS implantation 
techniques do vary between studies, however. Previously, 
in AIDA, we found that optimized Absorb BVS implanta-
tion techniques stratified by proposed reference vessel based 
(RVD) PSP scoring [8] showed numerically similar rates of 
target lesion revascularization (TLR) and scaffold thrombo-
sis through 30 months follow-up, with a median follow-up 
707 days [10].
In the current AIDA trial QCA substudy, we investigate 
the influence of dedicated device implantation techniques, 
including the more precise definition of Dmax based device 
sizing, on lesion-oriented outcomes in both Absorb BVS and 
Xience EES treated lesions at complete 3-year follow-up, a 
significant milestone in the device absorption process.
Materials and methods
Study design AIDA trial
The AIDA trial compared Absorb BVS versus Xience 
EES in routine clinical practice. The study design [11], 
the preliminary safety report [4], and the 2-year results 
[12] have been published previously. At complete 2-year 
follow-up, Absorb BVS was non-inferior to Xience EES 
for the primary endpoint of TVF (composite of cardiac 
death, target vessel revascularization and—myocardial 
infarction). Absorb BVS was, however, associated with 
increased rates of device thrombosis.
Design of the current analysis
QCA analysis
The current analysis includes all study lesions treated with 
at least one study device, of which the baseline angio-
gram was suited for offline QCA analysis, including Dmax 
analysis. QCA was performed with dedicated offline soft-
ware (Cardiovascular Angiography Analysis System, ver-
sion 5.11; Pie Medical Imaging, Maastricht). Offline QCA 
analyses were initially performed (January 2017) on the 
post-procedural angiograms with the Absorb BVS arm. 
We later added 5 experiences readers to our academic 
Corelab, in order to perform pre-procedural measures on 
the Absorb BVS arm, and perform both pre-procedural 
and post-procedural measures on the Xience EES arm. All 
QCA readers were blinded for events and were supervised 
by one QCA expert cardiologist [YO]. Pre-and post-pro-
cedural measurements were performed in either (1) mul-
tiple matched views or (2) a singled matched view. If no 
matched views were available, measurements were done 
within the view with the highest stenosis grade.
Definitions
Pre-dilatation was scored as ‘performed’ or not ‘per-
formed’, and was further sub-categorized into ‘performed 
with a balloon/reference vessel diameter (RVD) ratio of 
≥ 1:1’. We used multiple definitions for ‘sizing’. Vessel 
sizing was considered to be correct if the pre-procedural 
RVD was  ≥ 2.25 mm and ≤ 3.75 mm.
For Absorb BVS, the available device diameters were 
2.50 mm, 3.00 mm and 3.50 mm. For Xience EES, the 
available device diameters were 2.25  mm, 2.50  mm, 
2.75 mm, 3.00 mm, 3.50 mm and 4.00 mm. We applied 
the sizing definitions of the Instructions for Use of Absorb 
BVS and Xience EES. We considered implanted device 
and QCA derived diameter to be matched if the QCA 
diameter minus the device diameter fell within the range 
of ≥ − 0.25 to < 0.25. For the smallest available Absorb 
BVS (2.50 mm) and Xience EES (2.25 mm) the QCA 
diameter minus the device diameter had to fell within the 
range of  ≥ 0.00 to < 0.25. The range of reference vessel 
implantation was therefore ≥ 2.50 mm to  ≤ 3.75 mm for 
Absorb BVS, and ≥ 2.25 to ≤ 4.25 mm for Xience EES.
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Lesion oriented endpoints
The lesion-oriented composite outcome (LOCE) of this 
analysis was a composite of definite device thrombosis, 
target lesion revascularization and target-vessel myocar-
dial infarction (TV-MI). An independent clinical event 
committee adjudicated all reported events. All myocar-
dial infarction were defined by the Academic Research 
Consortium definitions.
Statistical analysis
This report provides information of the influence of 
implantation techniques on lesion-oriented outcomes at 
3-year follow-up within Absorb BVS and Xience EES 
treated lesions in the AIDA trial. Continuous variables 
are reported as mean ± SD. Event rates were based on 
Kaplan–Meier estimates. Kaplan–Meier event curves were 
compared by means of the log-rank test. The Cox regres-
sion analysis was used to determine hazard ratios with 
95% confidence intervals. All statistical analyses were 
performed with use of SPSS software, version 23 (IBM 
Corp., Armonk NY, USA).
Results
Population
In AIDA, 924 patients were randomized to Absorb BVS 
and 921 were randomized to Xience EES. A total of 2446 
lesions were treated; 1237 lesions within the Absorb BVS 
arm and 1209 within the Xience EES arm. We excluded 
89 lesions that did not receive any study device. Complete 
QCA measures including pre-procedural proximal and distal 
Dmax assessment were available in 2152 lesions (87.9%). 
The total cohort included in the current analysis consists 
of 1054 Absorb BVS treated lesions and 1098 Xience EES 
treated lesions.
Procedural characteristics
Table 1 shows the baseline characteristics of the study 
lesions. Predilatation of the complete lesion, and multiple 
device implantation per lesion, occurred more frequently 
in Absorb BVS when compared versus Xience EES (97.4% 
versus 91.8%, p < 0.001 and 17.0% versus 12.6%, p = 0.004; 
respectively). Correct device to artery sizing according to 
the proximal Dmax occurred less often in Absorb BVS 
(27.7%) versus 33.9.3% in Xience EES (33.9%), (p = 0.417). 
Post-dilatation of the complete lesion occurred more fre-
quently in Absorb BVS (76.8% versus 48.7%, p < 0.001).
Lesion‑oriented outcomes
At complete 3-year follow-up the primary endpoint of LOCE 
had occurred in 97 Absorb BVS treated lesions versus 67 
Xience EES treated lesions.
The effect of implantation technique(s) on the outcomes 
LOCE and definite device thrombosis in Absorb BVS treated 
lesions are shown in Table 2. In Absorb BVS treated lesions, 
LOCE occurred numerically less in correctly QCA based 
sized vessels when compared to incorrect sized vessels; 
8.5% (58/696) versus 11.1% (39/358), p = 0.151. Absorb 
BVS implantation in vessels with a diameter < 2.25 mm 
showed a trend towards significance for higher rates of 
LOCE (12.6% versus 8.3%, p = 0.091) when compared to 
vessel with a diameter > 2.25 mm. In Absorb BVS devices, 
which were postdilated with a ≥ 1:1 NC balloon/device 
ratio at 18 atm., LOCE occurred in 11.2% (24/219) devices, 
whereas in devices, which weren’t postdilated with a ≥ 1:1 
NC balloon/device ratio at 18 atm, LOCE occurred in 6.3% 
(73/835) devices, (p = 0.337).
The effect of implantation technique(s) on the outcomes 
LOCE and definite device thrombosis in Xience EES treated 
lesions are shown in Table 3. At complete 3-year follow-up 
the primary endpoint of LOCE had occurred more frequently 
in incorrectly sized devices according to device diameter to 
RVD matching; 3.3% (7/220) in correctly sized devices ver-
sus 7.0% (60/878) in incorrectly sized devices (p = 0.044). 
In Xience EES devices, which were postdilatated with a ≥ 
1:1 NC balloon/device ratio at 18 atm., LOCE occurred in 
6.0% (9/157) devices, whereas in devices in which this was 
not performed, LOCE occurred in 6.3% (58/941) devices, 
(p = 0.863).
Figures 1 and 2 show the Kaplan–Meier curves of the 
influence of correct pre-dilatation, correct Dmax based 
device sizing, and correct post-dilation on LOCE in Absorb 
BVS and Xience EES treated lesions.
Landmark analyses from 0 to 30 days, and from 1 to 
3 years, of the influence of small vessel sizing, and artery/
RVD based sizing, on LOCE in the Absorb BVS and 
Xience EES arm are shown in Supplementary Figs. 1, 2, 3 
and 4. The effect of implantation technique(s) on the out-
comes of TLR and TV-MI in Absorb BVS and Xience EES 
treated lesions are shown in Supplementary Tables 1 and 2, 
respectively.
Discussion
The main findings of this explorative AIDA QCA substudy 
at complete 3 year follow-up are:
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1. The lesion-oriented composited endpoint occurred in 
97 Absorb BVS treated lesions and in 67 Xience EES 
treated lesions. Event rates of LOCE were, significantly 
lower in Xience EES treated lesions, in which devices 
were correctly sized according to the definitions of 
device diameter / RVD matching. The event rates in 
Xience were also numerically lower in correctly sized 
vessel and in lesions in which devices were correctly 
sized according to either the proximal, or the proximal 
and distal, Dmax.
2. The results of this study indicate that lesion-oriented 
outcomes with Xience EES might improve with use 
of QCA dedicated implantation strategies whereas, in 
Absorb BVS no improvement was found.’
This study investigates the influence of implantation 
techniques on lesion-oriented outcomes of Absorb BVS 
or Xience EES treated lesions in routing clinical practice. 
Implantation techniques, or combined PSP implantation 
strategies, have been carefully analyzed in order to search 
for provoking factors that may attribute to higher rates of 
scaffold or stent failure [9]. To date, however, the exact defi-
nition of correct combined PSP implantation strategies and 
techniques, and the consequent effect and/or results, have 
been varying between studies [8–10]. In AIDA, we found 
no correlation between optimized Absorb BVS implantation 
techniques and lesion-oriented outcomes. Within the Xience 
EES treated lesions, however, we did find that correct RVD 
based sizing cut the rates of LOCE in half, indicating that 
Table 1  Procedural characteristics
BVS bioresorbable vascular scaffold, EES everolimus eluting stent, QCA quantitative coronary angiography
Absorb BVS Xience EES P value
Treated lesions
 Total number of lesions 1054 1098
  Rotational atherectomy 22/1051 (2.1%) 25/1097 (2.3%) 0.883
  Thrombus present 145 (13.8%) 144 (13.1%) 0.704
  Bifurcation lesion 54 (5.1%) 63 (5.7%) 0.569
  Ostial lesion 55 (5.2%) 62/1097 (5.7%) 0.704
Pre-dilation
 Pre-dilatation of the complete lesion performed 1027 (97.4%) 1008 (91.8%)  < 0.001
  Balloon diam/RVD ratio ≥ 1:1 617 (58.5%) 579 (52.7%) 0.007
Device implantation
 Number of devices per lesions 1.19 ± 0.45 1.14 ± 0.38 0.003
  Single device per lesion, n (%) 875 (83.0%) 960 (87.4%) 0.004
  Multiple devices per lesion, n (%) 179 (17.0%) 138 (12.6%) 0.004
  Total device length 23.80 ± 11.75 22.87 ± 11.34 0.061
  Correct vessel sizing (≥  2.25 mm and ≤ 3.75 mm) 696/1095 (66.0%) 705/1095 (64.2%) 0.390
  Vessel diameter < 2.25 mm 336 (31.9%) 365 (33.2%) 0.520
  Vessel diameter > 3.75 mm 20 (1.9%) 25 (2.3%) 0.551
  Correct device/artery sizing according to RVD 187 (17.7%) 220 (20.0%) 0.186
  Correct device/artery sizing according to prox Dmax 292 (27.7%) 372 (33.9%) 0.002
  Correct device/artery sizing according to prox and distal Dmax 128 (12.1%) 148 (13.5%) 0.367
Post-dilatation
 Of the complete lesion 809 (76.8%) 535 (48.7%)  < 0.001
  Performed with ≥ 1:1 balloon/device ratio 773 (73.3%) 502 (45.7%)  < 0.001
  Performed with a NC balloon 713 (67.6%) 445 (40.5%)  < 0.001
  Performed > 16 atm 385 (36.5%) 270 (24.6%)  < 0.001
  Performed > 18 atm 219 (20.8%) 157 (14.3%)  < 0.001
Target lesion measures
 Reference vessel diameter pre-procedure 2.53 ± 0.58 2.51 ± 0.62 0.435
  Percentage diameter stenosis pre-procedure (%) 57.05 ± 16.07 57.59 ± 16.30 0.524
  Percentage diameter stenosis post-procedure (%) 23.02 ± 10.42 25.85 ± 11.45  < 0.001
  Post-procedural minimum lumen diameter 2.01 ± 0.55 1.95 ± 0.50 0.010
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Table 2  Outcomes in Absorb BVS treated lesions
It shows the outcomes of the Lesion-Oriented Composite Endpoint (LOCE) and device thrombosis in Absorb BVS treated lesions
Lesion-oriented composite endpoint Definite scaffold thrombosis
Performed Not performed HR (95% CI) P value Present Not present HR (95% CI) P value
Predilation parameters
 Predilatation of 
the complete 
lesion per-
formed
10.3% (94/1024) 10.4% (3/27) 0.80 (0.25–2.54) 0.708 3.0% (30/1054) 3.8% (1/27) 0.78 (0.11–5.75) 0.811
 Predilatation 
balloon/RVD 
1:1
10.2% (62/617) 8.2% (35/437) 1.29 (0.85–1.95) 0.232 3.0% (18/617) 3.0% (13/437) 0.99 (0.49–2.02) 0.976
Sizing
 Correct device/
artery sizing 
according to 
RVD
10.8% (20/187) 9.0% (77/867) 1.19 (0.73–1.94) 0.498 4.9% (9/187) 2.6% (22/867) 1.88 (0.87–4.10) 0.105
 Correct device/
artery sizing 
according to 
prox Dmax
10.1% (29/292) 8.9% (68/762) 1.11 (0.72–1.71) 0.643 4.2% (12/292) 2.5 (19/762) 1.64 (0.80–3.38) 0.174
 Correct device/
artery sizing 
according 
to prox and 
distal Dmax
9.5% (12/128) 9.3% (85/926) 0.99 (0.54–1.82) 0.980 3.2% (4/128) 3.0% (27/926) 1.05 (0.37–3.00) 0.931
 Correct QCA 
based artery 
sizing (≥ 2.25 
and ≤ 3.75)
8.5% (58/696) 11.1% (39/358) 0.74 (0.50–1.12) 0.151 3.2% (22/696) 2.5% (9/358) 1.25 (0.57–2.70) 0.579
 Small vessel 
(< 2.25 mm)
12.6% (38/336) 8.3% (59/718) 1.42 (0.94–2.13) 0.091 2.7% (9/336) 3.1% (22/718) 0.88 (0.41–1.92) 0.753
 Large vessel 
(> 3.75 mm)
5.3% (1/20) 9.4% (96/1034) 0.54 (0.08–3.86) 0.530 0% (0/20) 3.0% (31/1034) 0.05 (0.00– > 100) 0.440
Postdilatation parameters
 Postdilatation 
of the com-
plete lesion
8.9% (79/809) 7.5% (18/245) 1.34 (0.80–2.23) 0.263 3.3% (26/809) 2.1% (5/245) 1.58 (0.61–4.13) 0.342
 Performed 
with ≥ 1:1 
balloon/
device ratio
9.8% (74/773) 8.3% (23/281) 1.18 (0.74–1.88) 0.493 3.2% (24/773) 2.5 (7/281) 1.26 (0.54–2.91) 0.596
 Performed with 
a NC balloon
9.7% (68/713) 8.6% (29/341) 1.13 (0.73–1.74) 0.591 3.3% (23/713) 2.4% (8/341) 1.39 (0.62–3.10) 0.422
 Performed 
with ≥ 16 atm
10.3% (39/375) 8.8% (58/669) 1.17 (0.78–1.75 0.453 3.2% (12/375) 2.9% (19/669) 1.09 (0.53–2.25) 0.807
 Performed 
with  ≥ 18 atm
11.2% (24/219) 8.9% (73/835) 1.25 (0.79–1.99) 0.337 4.2% (9/219) 2.7% (22/835) 1.57 (0.72–3.40) 0.253
PSP parameters
 Lesion treated 
PSP (Correct 
Dmax/device 
sizing)
11.1% (2/18) 9.3% (95/1036) 1.17 (0.29–4.74) 0.828 (0/18) (31/1036) 0.05 (0.00– > 100) 0.456
 Lesion treated 
PSP (Correct 
vessel sizing)
11.1% (12/110) 9.2% (85/944) 1.23 (0.67–2.26) 0.497 2.8% (3/110) 3.0% (28/944) 0.93 (0.28–3.04) 0.897
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Table 3  Outcomes in Xience EES treated lesions
It shows the outcomes of the Lesion-Oriented Composite Endpoint (LOCE) and device thrombosis in Xience EES treated lesions
Lesion-oriented composite endpoint Definite stent thrombosis
Present Not present HR (95% CI) P value Present Not present HR (95% CI) P value
Predilation parameters
 Predilatation of 
the complete 
lesion per-
formed
6.3% (62/1008) 5.7% (5/90) 1.10 (0.44–2.72) 0.845 0.4% (4/1008) 1.1% (1/90) 0.36 (0.04–3.18) 0.333
 Predilatation bal-
loon/RVD 1:1
7.4% (42/579) 5.0% (25/519) 1.52 (0.92–2.49) 0.097 0.5% (3/579) 0.4% (2/519) 1.35 (0.23–8.05) 0.745
Sizing
 Correct device/
artery sizing 
according to 
RVD
3.3% (7/220) 7.0% (60/878) 0.45 (0.21–1.00) 0.044 0.5% (1/220) 0.5% (4/878) 1.00 (0.11–8.91) 0.997
 Correct device/
artery sizing 
according to 
prox Dmax
6.0% (22/372) 6.4% (45/726) 0.96 (0.58–1.60) 0.882 0.8% (3/372) 0.3% (2/726) 2.94 (0.49–17.57) 0.215
 Correct device/
artery sizing 
according to 
prox and distal 
Dmax
4.8% (7/148) 6.5% (60/950) 0.74 (0.34–1.62) 0.450 0.7% (1/148) 0.4%(4/950) 1.61 (0.18–14.36) 0.669
 Correct QCA 
based artery 
sizing (≥ 2.25 
and ≤ 3.75)
5.6% (38/705) 7.5% (29/393) 0.73 (0.45–1.180 0.190 0.3% (2/705) 0.8% (3/393) 0.37 (0.62–2.22) 0.258
 Small vessel 
(< 2.25 mm)
7.5% (27/365) 5.6% (40/733) 1.36 (0.84–2.22) 0.215 0.8% (3/365) 0.3% (2/733) 3.01 (0.50–18.01) 0.204
 Large vessel 
(> 3.75 mm)
4.0% (1/25) 6.3% (66/1073) 0.67 (0.09–4.85) 0.693 0% (0/25) 0.5% (5/1073) 0.05 (0.00– > 100) 0.734
Postdilatation parameters
 Postdilatation of 
the complete 
lesion
6.9% (36/535) 5.6% (31/563) 1.24 (0.77–2.00) 0.381 0.6% (3/535) 0.4% (2/563) 1.59 (0.27–9.48) 0.611
 Performed 
with ≥ 1:1 
balloon/device 
ratio
6.5% (32/502) 6.0% (35/596) 1.09 (0.68–1.77) 0.714 0.4% (2/502) 0.5% (3/596) 0.79 (0.13–4.74) 0.798
 Performed with a 
NC balloon
6.4% (28/445) 6.1% (39/653) 1.06 (0.65–1.72) 0.822 0.4% (2/445) 0.5% (3/653) 0.98 (0.16–5.85) 0.981
 Performed 
with ≥ 16 atm
6.4% (17/270) 6.2% (50/828) 1.04 (0.60–1.80) 0.888 0% (0/270) 0.6% (5/828) 0.03 (0.00– > 100) 0.201
 Performed 
with ≥ 18 atm
6.0% (9/157) 6.3% (58/941) 0.93 (0.46–1.88) 0.847 0% (0/157) 0.5% (5/941) 0.04 (0.00– > 100) 0.361
PSP parameters
 Lesion treated 
PSP (Correct 
Dmax/device 
sizing)
11.8% (2/17) 6.2% (65/1081) 1.96 (0.48–8.01) 0.339 0% (0/17) 0.5% (5/1081) 0.05 (0.00– > 100) 0.778
 Lesion treated 
PSP (Correct 
vessel sizing)
6.9% (5/76) 6.2% (62/1022) 1.08 (0.44–2.70) 0.863 0% (0/76) 0.5% (5/1022) 0.05 (0.00– > 100) 0.542
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Fig. 1  The influence of correct 
predilatation (a), correct Dmax 
based sizing (b) and correct 
post-dilatation (c) on lesion-ori-
ented outcomes in Absorb BVS 
treated lesions. Predilatation 
was score correct if performed 
with a balloon/reference vessel 
diameter (RVD) ratio of  ≥ 1:1. 
Dmax based sizing was score 
correct if there was a match 
between proximal device diam-
eter and proximal Dmax, and 
the distal device diameter and 
distal Dmax. Correct was scored 
as correct if performed with a 
balloon/RVD ratio ≥ 1:1 (but no 
greater than 0.5 than that of the 
widest scaffold) with 18 atm.’
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optimized device implantation techniques may improve 
patients outcomes. Hence, we actually do not doubt that an 
adequate implantation strategy with structured predilatation, 
device sizing and post-dilatation, supported by additional 
QCA, intra-coronary imaging and/or (non)-invasive physiol-
ogy testing, is a correct stent or scaffold implantation strat-
egy. In the case of the Absorb BVS treated lesions, however, 
the intrinsic device limitations, and the device its inability to 
overexpand, may have likely attributed to the lack of effect 
of implantation techniques on lesion-oriented outcomes, and 
the consequent failure of the device.
Due to expansion limits of the Absorb bioresorbable 
scaffold a meticulous implantation with correct sizing is 
required. In routine PCI, intracoronary imaging is not man-
datory, and therefore the ability to correctly size a coronary 
vessel, and to consequently match the device to coronary 
artery diameter, is limited. Implantation of Absorb BVS in 
small vessels, has been widely associated with increased 
rates of adverse events at short and long-term follow-up 
[9]. In our study, we found that Absorb BVS implantation 
in smalls vessel was also associated with LOCE, but we 
did not find an association between Absorb BVS implan-
tation in small vessels and scaffold thrombosis. We also 
found no relation between any correct device/artery match-
ing based scaffold sizing strategy in Absorb BVS treated 
lesions. In contrast in Xience EES treated lesions alone 
correct device diameter / RVD based sizing was associated 
with significantly lower rates of LOCE. These results might 
indicate a certain unpredictability or incorrigibility in the 
occurrence of LOCE in Absorb BVS treated lesions, perhaps 
caused by the thicker and wider struts of the Absorb BVS 
and its inability to over-expand and embed deeply into the 
vessel.
We furthermore found slightly increased event rates 
when Absorb BVS was aggressively post-dilated. In con-
trast within Xience EES treated lesions, event rates dropped 
slightly when the device was more aggressively post-dilated.
In routine PCI, lesions which received post-dilatation 
might have been lesions with the greatest % residual ste-
nosis after Absorb BVS implantation. Potentially, in these 
more complex lesions, the device limitations of the Absorb 
BVS, such as the limited ability to over-expand and the lower 
radial and tensile strength, are therefore more likely to be 
unmasked, making it impossible to improve the implanta-
tion with any technique and eventually resulting in higher 
event rates. Combined PSP strategies, should be interpreted 
with some caution, since bias is likely to be introduced when 
combining aggregate implantation strategies in (more) com-
plex lesions.
The real potential benefits of BRS lays in the long-term, 
well after the period of complete scaffold absorption and 
resorption. Long-term follow-up of Absorb BVS treated 
patients therefore still remains necessary, in order evaluate 
whether the risk of adverse events declines after time. In 
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Fig. 2  The influence of correct 
predilatation (a), correct Dmax 
based sizing (b) and correct 
post-dilatation (c) on lesion-ori-
ented outcomes in Xience EES 
treated lesions. Predilatation 
was score correct if performed 
with a balloon/reference vessel 
diameter (RVD) ratio of ≥ 1:1. 
Dmax based sizing was score 
correct if there was a match 
between proximal device diam-
eter and proximal Dmax, and 
the distal device diameter and 
distal Dmax
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future studies, the selection bias may also be avoided by bet-
ter, and more specified, patient and lesion selection poten-
tially supported by the use of the SYNTAX (II) score, which 
has shown to be a feasible and clinically applicable tool for 
rapid risk stratification in patients who undergo PCI pre-
senting with a wide range of symptoms that may vary from 
stable coronary artery disease, to presentation with STEMI 
complicated by cardiogenic shock [13, 14]. Moreover, in 
future pre-clinical and clinical studies, careful longitudinal 
intracoronary imaging should play an important role in the 
investigation of (1) the device resorption and absorption 
process and (2) the effect of device specific implantations 
techniques.
Although Absorb BVS has been withdrawn from the com-
mercial market, the insights provided by this study could be 
helpful for the development of future coronary bioresorbable 
scaffolds, with optimized device characteristics and better 
resorption profiles.
Limitations
In AIDA and in routine PCI, device sizing based on online 
QCA is not mandatory, and therefore, incorrect device siz-
ing is likely to have occurred more frequently. Second, rou-
tine intracoronary imaging, such as OCT or IVUS, is not a 
part of routine PCI and therefore the study does not provide 
mechanistic insights in the occurrence of events due to a 
device/artery mismatch. Third, the role of lesion morphol-
ogy and typology stratification as a prognostic facture for 
device failure has not been analyzed in the current explora-
tive analysis. The gold standard for lesion morphology and 
typology stratification is intracoronary imaging. The AIDA 
population reflects routine PCI, and since intracoronary 
imaging is not a part of routine PCI (used in less than 10% 
of the cases), it was not possible to explore the exact role 
of these factors in this substudy. Furthermore, as with all 
post-hoc analyses, this AIDA trial sub-study is subject to 
under powering.
Conclusions
In this AIDA trial QCA substudy, rates of LOCE were sig-
nificantly lower in Xience EES treated lesions in which 
devices were correctly sized according to the definitions of 
device diameter/RVD matching. The results of this study 
indicate that lesion-oriented outcomes with Xience EES 
might improve with use of QCA dedication implantation 
strategies whereas in Absorb BVS no potential improvement 
was found.
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